Skip to main content
Equibles
MNKD logo

MNKD · Mannkind Corp

Track MNKD — free

Use MNKD with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research MNKD.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$3.75 -0.04 (-1.06%) At close · Sep 11
Russell 2000 member Rebalance outlook locked
Market Cap
$1.22B
Shares
321.54M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$3.75 Open$3.83 Day$3.73–3.85 52W close$2.28–6.21 Avg vol 30d3.9M Short int26.6M · 8.3% float · 8.5d Short vol60% Last earningsAug 5, 2026 DataJan 2020–Sep 2026 Filing10-Q · Aug 5

Up next

Next earnings call
Nov 4, 2026 Est · unconfirmed · in 8 wks
Latest filing: 10-Q
filed Aug 5, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$393.63M
Trailing 12 months
Net income (TTM)
−$43.61M
Trailing 12 months
Revenue growth YoY
+42.9%
Year over year
Operating margin
2.3%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-1.5%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-0.7%
Year over year · fewer shares
Price change (1Y)
-32.0%
Trailing year
Short interest
8.3%
Latest settlement · 8.5 days to cover
View all 115 metrics

AI Brief

Q2 FY26 earnings call · Aug 5, 2026
Q2 FY26

TL;DR. MannKind delivered all three 2026 catalysts: Afrezza pediatric approval and launch, Furoscix ReadyFlow FDA approval with late-August availability, and positive nintedanib DPI Phase 1b data enabling Phase 2 advancement. Q2 revenue rose 43% YoY to $109.4M but GAAP net loss widened to $19M as planned investments in launches and the MNKD-201 program ramped.

Bullish
  • + Delivered all three stated 2026 catalysts, including Afrezza pediatric approval, Furoscix ReadyFlow approval, and positive nintedanib DPI Phase 1b data.
  • + Furoscix Q2 net sales were $22.2M, with IDN doses up 36% and nephrology units up 67% over Q1.
  • + Afrezza pediatric launch is off to a strong early start, with 1 in 3 of the top 100 pediatric rapid-acting writers having prescribed.
  • + Closed a $50M PIPE, giving pro forma cash of $161M to fund the $45M CVR and support launches and MNKD-201 development.
Bearish
  • − Q2 GAAP net loss was $19M vs. $0.7M net income in Q2 2025, driven primarily by planned investments in launches and the MNKD-201 program plus the larger post-scPharma cost base.
  • − Afrezza Q2 net sales fell 7% YoY to $17.0M as adult resources were pulled back, and Q2 V-Go sales fell 33% YoY.
  • − Gross margin percentage decreased YoY due to inclusion of the lower-margin Furoscix product.
  • − R&D expense rose 32% YoY to $18.0M and SG&A rose 84% YoY to $58.3M as the company funds two launches and pipeline development.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Strong Sentiment Bullish Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 15.8 · calm Equity put/call 0.60
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −9%
below
Price vs 50-day avg −7%
below
RSI (14) 42
neutral
MACD trend Negative
52-week position 37%
mid-range
Momentum
relative strength
Strong
1-month return +1%
trailing
6-month return +52%
trailing
YTD return −34%
this year
Relative strength +34%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow Accumulating
+2% holders QoQ · +51 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
8.26% of float · ▼ -7.1% MoM · 8.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
259 holders — near 3-yr high, broad support
Squeeze score 68
elevated · 0–100
Fundamentals
Fair
Revenue growth +22%
Y/Y
EPS growth −80%
Y/Y
Free cash flow $13.7M
Balance sheet $89.0M
net debt
Quant / Vol
risk profile
Very High
Volatility 68%
annualized · 1-yr
Max drawdown −63%
past year
ATR 5.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed Mar 31, 2026
full-year 2026
FURO6 revenue Initiated $110M – $120M
this year
FURO6 sales $110M – $120M
Prior guidance period ended · from the Earnings Call filed Feb 25, 2021
Gross to net percentage · 2021 40% – 42%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−9% Bearish
Price vs 50-day avg
−7% Bearish
RSI (14)
42 Neutral
MACD trend
Negative Bearish
52-week position
37% Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow Accumulating
+2% holders QoQ · +51 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
8.26% of float · ▼ -7.1% MoM · 8.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
259 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $2 Now $4 · 37% Range high $6
vs 200-day avg -9% vs 50-day avg -7%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
MNKD
Mannkind Corp
this stock
$1.22B -33.9% +22.2% — 8.3%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.40B +13.7% +46.2% 30.0 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.67B +1.2% +20.8% 19.6 2.5%
ARGX
Argenx SE
 $61.60B +17.1% — — 2.0%
CSLLY
Csl Ltd
 $57.41B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
259
% held
57.4%
Net QoQ
+1.2M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
166
View
Short & Settlement
Short Interest Falling
Shares short
26.6M
Days to cover
8.5d
Change
-2.0M sh
View
Short Volume
Short vol %
60%
As of
Sep 11, 2026
Short Total
View
Fails to Deliver
FTD shares
67.8K
Value
$252.7K
As of
Aug 14, 2026
View
Off-Exchange
Off-exchange %
47.0%
Week of
Aug 3, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$349.0M
Net income (FY)
$5.9M
EPS diluted
$0.02
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 21, 2026
This year
13
View
Proposed Sales
Value
$132.2K
Shares
33.6K
Filed
Sep 10, 2026
View
Earnings & Events
Earnings Calls
Last call
Aug 5, 2026
View

Performance

5D 20D 120D MTD YTD
MNKD -5.3% +0.5% +51.8% -6.5% -33.9%
SPY -1.2% -1.8% +17.8% -0.4% +12.1%
vs SPY -4.2% +2.3% +34.0% -6.1% -45.9%
Key facts CIK 899460 CUSIP 56400P706 13F (30d) 112 filings 112 filers Visit website Investor relations